搜索
Search
这是描述信息

News Center

Expert consensus: Livzon Antiviral Granules are recommended for mild and common infections of COVID-19
Expert
2022-04-20
View details
Livzon Rapid Test for 2019-nCoV-2 Antigen (Lateral Flow) approved by China NMPA.
Livzon
View details
A Recombinant SARS-Cov-2 Fusion Protein Vaccine (V-01) developed and manufactured by Livzon has shown good protective effects against the Omicron variant in a phase III clinical booster trial
A
2022-04-20
View details
Livzon Pharmaceutical Group was recognized as the National Enterprise Technology Center with High Scores
Livzon
View details
Livzon participated in the 39th Annual JP Morgan Medical Health Conference
Livzon
Livzon participated in the 39th Annual JP Morgan Medical Health Conference
2021-01-15
View details
Environmental，Social and Governance Report 2019
Environmental，Social
Since the new round of medical and health system reforms launched in China in 2009, a complete basic
medical insurance system has been gradually established and major health indicators of the residen
View details
Since the new round of medical and health system reforms launched in China in 2009, a complete basic
medical insurance system has been gradually established and major health indicators of the residen
Livzon Win in the Drug Tender of Hong Kong
Livzon
Livzon Win in the Drug Tender of Hong Kong
View details
Livzon Win in the Drug Tender of Hong Kong
Livzon Group Won “Top 10 of Private Enterprise in Zhuhai”
Livzon
2012-09-10
Livzon Group Won “Top 10 of Private Enterprise in Zhuhai”
View details
Livzon Group Won “Top 10 of Private Enterprise in Zhuhai”
Previous page
1
2
3
4
5

Add: No.38, Chuangye North Road, Jinwan District, Zhuhai, Guangdong, P.R.China    Tel： 0756-8135888    

©2021 Livzon  Support：300.cn

Home | E-Mail | Legal Declaration

Add: No.38, Chuangye North Road, Jinwan District, Zhuhai, Guangdong, P.R.China  

©2021 Livzon   

 Support：300.cn